News | News By Subject | News by Disease News By Date | Search News

Scleroderma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Galapagos NV (GLPG.BR) Subsidiary BioFocus DPI Lines Up $31 Million Windfall From Agreement With Biogen Idec, Inc. (Massachusetts) (BIIB)     11/12/2013
Daval International Limited Announces Positive Phase II Results for AIMSPRO(R) as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)     10/10/2011
Novartis Pharmaceuticals Corporation (NVS)' Afinitor Study Met Key Goal Of Tumor-size Reduction In TSC Patients     7/11/2011
Pfizer Inc. (PFE) Submits Regulatory Filings For Revatio As A Treatment For Pulmonary Arterial Hypertension     12/3/2004
Cambridge Antibody Technology Group (CATG) And Genzyme Corporation (GENZ) Announce Preliminary Results From Phase I/II Trial Of Cat-192 For Scleroderma; Skin Score Did Not Deteriorate During The Trial As Anticipated     2/9/2004

News from Around the Web

Press Releases
Cytori Therapeutics (CYTX) Announces Enrollment Completion In U.S. Phase III Scleroderma Trial     6/7/2016
European Scleroderma Trial Investigating Cytori Therapeutics (CYTX) Cell Therapy To Be Presented In Japan     5/17/2016
Cytori Therapeutics (CYTX) Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial     4/27/2016
Cumberland Pharmaceuticals (CPIX) Announces New Program To Develop Vasculan For Systemic Sclerosis     4/27/2016
ProMetic Life Sci (PFSCF.PK) Announces The Addition Of Scleroderma To PBI-4050's Targeted Indications     3/15/2016
Data Reports Sustained Benefit At Two Years With Single Administration Cytori Therapeutics (CYTX) Cell Therapy For Scleroderma     2/22/2016
Cytori Therapeutics (CYTX) Management To Discuss Scleroderma Clinical Trial Findings     2/22/2016
Cytori Therapeutics (CYTX) Release: Scleroderma Two Year Data To Be Presented At The 4th Systemic Sclerosis World Congress     2/10/2016
Cytori Therapeutics, Inc. (CYTX) To Provide Corporate Update At 2016 Biotech Showcase     1/6/2016
Boehringer Ingelheim Release: New Phase III Study Of Nintedanib In People With Systemic Sclerosis And Lung Fibrosis Launched     12/8/2015
Enrollment Initiated In Cytori Therapeutics, Inc. (CYTX) European Scleroderma Trial     10/19/2015
Cytori Therapeutics, Inc. (CYTX) To Provide Corporate Update And Investor Presentation Live, At VirtualInvestorConferences.com September 10     9/3/2015
Cytori Therapeutics, Inc. (CYTX) Reports Second Quarter 2015 Business and Financial Results     8/7/2015
Enrollment Begins In Cytori Therapeutics, Inc. (CYTX) U.S. Phase III/Pivotal Scleroderma Trial     8/6/2015
Cancer Drug Shows Promise for Treating Scleroderma, Hospital for Special Surgery Study     3/28/2011

//-->